GlassScriptPhysician profile
Shannon M Sherfey
NPI 1073572210
$4,414.19
in general payments reported to CMS, 2019-2025
47 companies · $749 in 2025
The $749 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $951 · 2020: $298 · 2021: $337 · 2022: $675 · 2023: $728 · 2024: $676 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,152.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $722.55 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $508.40 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $390.08 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $334.93 | 2019-2024 | Prolia, Evenity |
| Abbvie INC. | $232.43 | 2019-2025 | Ubrelvy, Vraylar |
| Dexcom, INC. | $228.39 | 2023-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $215.72 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $174.46 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $148.06 | 2019-2024 | Arexvy, Shingrix |
| Amneal Pharmaceuticals LLC | $138.92 | 2023-2025 | Unithroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.13 | 2020-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $104.19 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $89.89 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $88.74 | 2022 | |
| Merck Sharp & Dohme LLC | $60.49 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Sherfey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.